Immunotherapy Advances : Impact Factor & More
eISSN: 2732-4303
Open AccessShare this on:
Key Metrics
SJR 
Q4Mathematics (all)
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Immunotherapy Advances
Immunotherapy Advances Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 2100 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Publication Details | |
| Publication Time | 7 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Immunotherapy Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Immunotherapy Advances
Combination of proton-pump inhibitor and anti-CD3 F(ab\u2019)2 for islet neogenesis and immune modulation in type 1 diabetes
- 22 Jul 2026
- Immunotherapy Advances
Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer
- 15 Jul 2026
- Immunotherapy Advances
The resilient subset: cancer stem cells at the core of immunotherapy resistance
- 6 May 2026
- Immunotherapy Advances
Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro
- 1 Apr 2026
- Immunotherapy Advances
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.
- 21 Feb 2026
- Immunotherapy advances
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
- 9 Jan 2026
- Immunotherapy Advances
Combination of proton-pump inhibitor and anti-CD3 F(ab\u2019)2 for islet neogenesis and immune modulation in type 1 diabetes
- 22 Jul 2026
- Immunotherapy Advances
Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer
- 15 Jul 2026
- Immunotherapy Advances
The resilient subset: cancer stem cells at the core of immunotherapy resistance
- 6 May 2026
- Immunotherapy Advances
Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro
- 1 Apr 2026
- Immunotherapy Advances
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.
- 21 Feb 2026
- Immunotherapy advances
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
- 9 Jan 2026
- Immunotherapy Advances
FAQs on Immunotherapy Advances
How many articles did Immunotherapy Advances publish last year? 
What is the SJR for Immunotherapy Advances?
Who is the publisher of Immunotherapy Advances?
